Cipla targets South African asthma market with breath activated inhaler

By Gareth Macdonald contact

- Last updated on GMT

iStock/decade3d
iStock/decade3d

Related tags: Asthma

Cipla has launched a breath activated inhaler in South Africa.

The product – known as Synchrobreathe – delivery a dose when the user inhalers, which will help sufferers of obstructive airway diseases – asthma and COPD, for example – manage their diseases more effectively according to Cipla Medpro CEO, Paul Miller.

Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South Africa​” Miller said.

South Africa has one of the highest asthma death rates in the world. According to a 2014 study by the Global Asthma Network​ around 15,000 people die from the disease each year.

Related topics: Drug Delivery, Delivery technologies

Related news

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars